Pharmacotherapy and Pregnancy: Highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy

Indiana University Center for Bioethics, Indianapolis, Indiana, USA
Clinical and Translational Science (Impact Factor: 1.43). 06/2011; 4(3):204 - 209. DOI: 10.1111/j.1752-8062.2011.00280.x
Source: PubMed


To address provider struggles to provide evidence-based, rational drug therapy to pregnant women, this third Conference was convened to highlight the current progress and research in the field. Speakers from academic centers, industry, and governmental institutions spoke about: the Food and Drug Administration’s role in pregnancy pharmacology and the new labeling initiative; drug registries in pregnancy; the pharmacist’s role in medication use in pregnancy; therapeutic areas such as preterm labor, gestational diabetes, nausea and vomiting in pregnancy, and hypertension; breast-feeding and medications; ethical challenges for consent in pregnancy drug studies; the potential for cord blood banks; and concerns about the fetus when studying drugs in pregnancy. The Conference highlighted several areas of collaboration within the current Obstetrics Pharmacology Research Units Network and hoped to educate providers, researchers, and agencies with the common goal to improve the ability to safely and effectively use individualized pharmacotherapy in pregnancy. Clin Trans Sci 2011; Volume 4: 204–209

Download full-text


Available from: Eric Meslin, Dec 26, 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Changes in maternal physiology during pregnancy can alter the absorption, distribution, and clearance of many drugs. When presented with a clinical situation in which it does not appear that a prescribed drug is working, clinicians must either change drugs or increase the dose of the current drug to achieve the desired clinical effect. A case highlighting antihypertensive medication in pregnancy and the effect of changed drug-metabolizing enzymes is presented. Understanding pregnancy's effect on drug-metabolizing enzymes, transporters, and receptors can help clinicians make individualized pharmacotherapeutic decisions for patients. Pharmacogenetics potentially can aid clinicians in treating pregnant women in the future as more data are generated and individualized therapeutic models are constructed.
    Obstetrics and Gynecology 11/2012; 120(5):1176-9. DOI:10.1097/AOG.0b013e3182698538 · 5.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: During pregnancy most of women will experience some kind of pain, either as a result of a pre-existing condition (low back pain, headache, fibromyalgia, and rheumatoid arthritis) or as a direct consequence of pregnancy (weight gain, postural changes, pelvic floor dysfunction, hormonal factors). However, chronic pain management during pregnancy and lactation remains a challenge for clinicians and pregnant women are at risk of undertreatment for painful conditions, because of fear about use of drugs during pregnancy. Few analgesic drugs have been demonstrated to be absolutely contraindicated during pregnancy and breastfeeding, but studies in pregnant women are not available for most of pain medications. The aim of this paper is to review the safety profile in pregnancy or lactation of the commonly prescribed pain medications and non-pharmacological treatments. In addition to the conventional classifications from the Food and Drug Administration and the American Academy of Paediatrics, authors analyzed the currently available clinical data from literature.
    Minerva anestesiologica 07/2013; 80(2). · 2.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are relatively few data reported on specific features of drug pharmacokinetics (PK) and pharmacodynamics in pregnancy compared to the non-pregnant state. Changes in maternal physiology and metabolic processes during pregnancy effect on PK and show that standard adult dosing is likely to be incorrect during pregnancy. Physiology-based pharmacokinetic (PBPK) model could be used to evaluate different dosing regimens for pregnant women and to correctly predict drug exposure and response on the personal level.
    Eksperimental'naia i klinicheskaia farmakologiia 05/2014; 77(2):35-43.